The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/foc.2.1.17

Schizophrenia is a chronic, debilitating psychotic disorder that affects 1% of adults. Symptoms of the illness are highly variable from person to person but typically include “positive” symptoms (delusions, hallucinations, thought disorganization), “negative” symptoms (blunted affect, social dysfunction, lack of motivation), cognitive impairments, and mood disturbance. Recurrence of active psychosis, progression of symptoms, and deterioration in all areas of life function are the rule. Given the combination of onset in early adulthood and persistent dysfunction, schizophrenia incurs enormous financial and personal costs. The biological basis of the disorder is not clear but is known to include genetic, environmental, and developmental factors. Recent research findings underscore the importance of dopamine systems and maturational changes in the brain. Treatment includes psychosocial interventions to address social deficits, family issues, and functional impairments and medication treatment to control symptoms. Atypical antipsychotic medications are used as first-line pharmacotherapy; clozapine is used for patients with treatment-refractory illness, and depot conventional antipsychotics are used for responsive but noncompliant patients. Optimal treatment is provided in community-based centers with expertise in the disorder. Ensuring adequate support for such treatment, however, is a continuing challenge.